Life quality assessment among adult patients with atopic dermatitis

Hee Jung Lee, Chang Ook Park, JuHee Lee, Kwanghoon Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Quantification of quality of life (QOL) related to disease severity is important in patients with atopic dermatitis (AD), because the assessment provides additional information to the traditional objective clinical scoring systems. Objective: We evaluated the association between QOL and severity scoring systems of AD. Methods: We assessed QOL, clinical severity scores, and total IgE in peripheral blood in 41 AD patients at our dermatology clinic over an 8 month period. QOL was assessed at two visits with a monthly interval by a dermatology-specific questionnaire (Dermatology Life Quality Index (DLQI)). Eczema Area and Severity Index (EASI) and Scoring of Atopic Dermatitis (SCORAD) was used to measure disease severity. Visual analogue scale (VAS) of pruritus and loss of sleep (LOS) were also recorded. Results: The mean DLQI was 11.6. For DLQI the dimension with the highest score was 26, and the lowest score was 2. DLQI did not correlate with EASI at visit 1, but correlated well with EASI at visit 2. Changes of DLQI in each patient between visits 1 and 2 were significant (p<0.05) and positively correlated with the severity scoring (EASI, SCORAD). In addition, the sum of VAS of pruritus and loss of sleep a correlated well with the DLQI and EASI at each visit. Conclusion: AD has a great impact on QOL of patients. Although the DLQI is known as an excellent method of measuring QOL in patients with dermatologic disease, correlation between DLQI and disease severity was not definite. However, changes of DLQI during follow-up significantly correlated with clinical course in each patient. Therefore, DLQI can be an important parameter when evaluating the disease course in AD patients.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalKorean Journal of Dermatology
Volume45
Issue number2
Publication statusPublished - 2007 Feb 1

Fingerprint

Atopic Dermatitis
Dermatology
Quality of Life
Eczema
Pruritus
Visual Analog Scale
Sleep
Immunoglobulin E

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{6d61c928a9e7496891bd52ccfdf1d442,
title = "Life quality assessment among adult patients with atopic dermatitis",
abstract = "Background: Quantification of quality of life (QOL) related to disease severity is important in patients with atopic dermatitis (AD), because the assessment provides additional information to the traditional objective clinical scoring systems. Objective: We evaluated the association between QOL and severity scoring systems of AD. Methods: We assessed QOL, clinical severity scores, and total IgE in peripheral blood in 41 AD patients at our dermatology clinic over an 8 month period. QOL was assessed at two visits with a monthly interval by a dermatology-specific questionnaire (Dermatology Life Quality Index (DLQI)). Eczema Area and Severity Index (EASI) and Scoring of Atopic Dermatitis (SCORAD) was used to measure disease severity. Visual analogue scale (VAS) of pruritus and loss of sleep (LOS) were also recorded. Results: The mean DLQI was 11.6. For DLQI the dimension with the highest score was 26, and the lowest score was 2. DLQI did not correlate with EASI at visit 1, but correlated well with EASI at visit 2. Changes of DLQI in each patient between visits 1 and 2 were significant (p<0.05) and positively correlated with the severity scoring (EASI, SCORAD). In addition, the sum of VAS of pruritus and loss of sleep a correlated well with the DLQI and EASI at each visit. Conclusion: AD has a great impact on QOL of patients. Although the DLQI is known as an excellent method of measuring QOL in patients with dermatologic disease, correlation between DLQI and disease severity was not definite. However, changes of DLQI during follow-up significantly correlated with clinical course in each patient. Therefore, DLQI can be an important parameter when evaluating the disease course in AD patients.",
author = "Lee, {Hee Jung} and Park, {Chang Ook} and JuHee Lee and Kwanghoon Lee",
year = "2007",
month = "2",
day = "1",
language = "English",
volume = "45",
pages = "159--164",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "2",

}

Life quality assessment among adult patients with atopic dermatitis. / Lee, Hee Jung; Park, Chang Ook; Lee, JuHee; Lee, Kwanghoon.

In: Korean Journal of Dermatology, Vol. 45, No. 2, 01.02.2007, p. 159-164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Life quality assessment among adult patients with atopic dermatitis

AU - Lee, Hee Jung

AU - Park, Chang Ook

AU - Lee, JuHee

AU - Lee, Kwanghoon

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Background: Quantification of quality of life (QOL) related to disease severity is important in patients with atopic dermatitis (AD), because the assessment provides additional information to the traditional objective clinical scoring systems. Objective: We evaluated the association between QOL and severity scoring systems of AD. Methods: We assessed QOL, clinical severity scores, and total IgE in peripheral blood in 41 AD patients at our dermatology clinic over an 8 month period. QOL was assessed at two visits with a monthly interval by a dermatology-specific questionnaire (Dermatology Life Quality Index (DLQI)). Eczema Area and Severity Index (EASI) and Scoring of Atopic Dermatitis (SCORAD) was used to measure disease severity. Visual analogue scale (VAS) of pruritus and loss of sleep (LOS) were also recorded. Results: The mean DLQI was 11.6. For DLQI the dimension with the highest score was 26, and the lowest score was 2. DLQI did not correlate with EASI at visit 1, but correlated well with EASI at visit 2. Changes of DLQI in each patient between visits 1 and 2 were significant (p<0.05) and positively correlated with the severity scoring (EASI, SCORAD). In addition, the sum of VAS of pruritus and loss of sleep a correlated well with the DLQI and EASI at each visit. Conclusion: AD has a great impact on QOL of patients. Although the DLQI is known as an excellent method of measuring QOL in patients with dermatologic disease, correlation between DLQI and disease severity was not definite. However, changes of DLQI during follow-up significantly correlated with clinical course in each patient. Therefore, DLQI can be an important parameter when evaluating the disease course in AD patients.

AB - Background: Quantification of quality of life (QOL) related to disease severity is important in patients with atopic dermatitis (AD), because the assessment provides additional information to the traditional objective clinical scoring systems. Objective: We evaluated the association between QOL and severity scoring systems of AD. Methods: We assessed QOL, clinical severity scores, and total IgE in peripheral blood in 41 AD patients at our dermatology clinic over an 8 month period. QOL was assessed at two visits with a monthly interval by a dermatology-specific questionnaire (Dermatology Life Quality Index (DLQI)). Eczema Area and Severity Index (EASI) and Scoring of Atopic Dermatitis (SCORAD) was used to measure disease severity. Visual analogue scale (VAS) of pruritus and loss of sleep (LOS) were also recorded. Results: The mean DLQI was 11.6. For DLQI the dimension with the highest score was 26, and the lowest score was 2. DLQI did not correlate with EASI at visit 1, but correlated well with EASI at visit 2. Changes of DLQI in each patient between visits 1 and 2 were significant (p<0.05) and positively correlated with the severity scoring (EASI, SCORAD). In addition, the sum of VAS of pruritus and loss of sleep a correlated well with the DLQI and EASI at each visit. Conclusion: AD has a great impact on QOL of patients. Although the DLQI is known as an excellent method of measuring QOL in patients with dermatologic disease, correlation between DLQI and disease severity was not definite. However, changes of DLQI during follow-up significantly correlated with clinical course in each patient. Therefore, DLQI can be an important parameter when evaluating the disease course in AD patients.

UR - http://www.scopus.com/inward/record.url?scp=34249702406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249702406&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 159

EP - 164

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 2

ER -